Navigation Links
Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
Date:3/4/2008

d disease

detection, classification and monitoring of prevalent cancers,

including ovarian, breast and prostate. Vermillion will have access to

exclusive commercial rights to the discoveries made through the

partnership.

-- Vermillion's stockholders and board of directors approved a 1 for 10

reverse stock split of the Company's common stock. The reverse split

became effective at the close of trading on Monday, March 3, 2008.

-- The Ohio State University commercially launched Vermillion's diagnostic

test for managing patients with TTP, a hematological disease. The test

helps physicians make the correct diagnosis, initiate timely treatment,

evaluate response to therapy and predict the risk of recurrence in

patients with TTP.

-- Received issuance of U.S. Patent No. 7,297,556 for aiding diagnosis of

nephrotic syndrome, a kidney disorder marked by very high or low levels

of protein in the urine, which results in bodily swelling and high

cholesterol.

2008 Milestones

The Company's primary goal for 2008 will be to commercialize its diagnostic tests through collaborations with Quest Diagnostics and other thought leaders in oncology, cardiology and hematology. Vermillion expects to attain the following milestones:

-- Present data from three studies highlighting progress in Vermillion's

ovarian cancer diagnostic program at the Society for Gynecologic

Oncologists' (SGO) 2008 Annual Meeting on Women's Cancer held

March 9-12 in Tampa, Florida.

-- Report top-line data from the ovarian tumor triage clinical trial later

this quarter and submit to the U.S. Food and Drug Administration (FDA)

for clearance as an in vitro diagnostic test in the first half of 2008.

-- Work with Quest Diagnostics to integrate Vermillion's PAD proteomic

biomarkers as a laboratory
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
10. Access Highlighted in Recent BusinessWeek Article
11. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, a ... Sales & Marketing Director. , With more than 25 years of experience ... reinforcing Tronics’ business development activities worldwide. He brings to the company his strong ...
(Date:7/30/2015)... July 30, 2015   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... announced that its strategic partner VetStem Biopharma, Inc. ... study of AT-016, an adipose-derived allogeneic stem cell ... of osteoarthritis pain in dogs. The ...
(Date:7/30/2015)... ST. LOUIS, July 30, 2015 ... period in 2014) , Reported sales were $697 ... of 2014.  Sales grew organically by 8%, and changes ... Recent acquisitions increased sales by 1%. , By ... 8% in Applied and 11% in SAFC Commercial. ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... for the second quarter of 2015. CEO ... and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in ... - Performance drivers - ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... , ... Researchers in New Brunswick Scientific's ... high antibiotic expression levels in a pilot-scale fermentation process ... with,touchscreen interface augmented by the powerful supervisory capabilities of ...
... , ... new cell-growth matrix that dramatically increase yields in packed-bed reactors, and,have ... bags. New Brunswick,Scientific offers two new devices that use FibraCel disks ... system that outperforms spinners, T-flasks and roller bottles, and the CelliGen ...
... , Many of ... application in cell culture and fermentation. ... or antigen from a sample (from,serum, for example) by adding the corresponding antigen or ... of substances in solution or suspension, to ...
Cached Biology Technology:Rapamycin Optimized in 100 Liter Fermentor Using BioCommand Control Strategys 2Rapamycin Optimized in 100 Liter Fermentor Using BioCommand Control Strategys 3A technique for increasing yields in bioreactors and disposable cell-culture systems 2A technique for increasing yields in bioreactors and disposable cell-culture systems 3A technique for increasing yields in bioreactors and disposable cell-culture systems 4Glossary for The BioPharm Guide to Fermentation and Cell Culture 2Glossary for The BioPharm Guide to Fermentation and Cell Culture 3Glossary for The BioPharm Guide to Fermentation and Cell Culture 4Glossary for The BioPharm Guide to Fermentation and Cell Culture 5Glossary for The BioPharm Guide to Fermentation and Cell Culture 6Glossary for The BioPharm Guide to Fermentation and Cell Culture 7Glossary for The BioPharm Guide to Fermentation and Cell Culture 8Glossary for The BioPharm Guide to Fermentation and Cell Culture 9Glossary for The BioPharm Guide to Fermentation and Cell Culture 10Glossary for The BioPharm Guide to Fermentation and Cell Culture 11Glossary for The BioPharm Guide to Fermentation and Cell Culture 12Glossary for The BioPharm Guide to Fermentation and Cell Culture 13Glossary for The BioPharm Guide to Fermentation and Cell Culture 14Glossary for The BioPharm Guide to Fermentation and Cell Culture 15Glossary for The BioPharm Guide to Fermentation and Cell Culture 16
(Date:7/23/2015)... , July 23, 2015 Research and ... of the "Global Outlook of the Biometrics ... The global biometrics market is ... and commercial applications owing to the uptake of ... a transformation that enhances the growth of biometrics ...
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/20/2015)... July 20, 2015  Acuity Market Intelligence,s latest ... Convergence of Commerce and Privacy" forecasts that between ... apps will be downloaded to smart mobile devices ... biometrics market is projected to generate more than ... the seven-year forecast period.    "Biometrics ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... According to a report from a CSIRO Wealth From Oceans ... Geophysical Research Letters since 1950 Victoria has suffered a ... compared to the average recorded between 196190. The reports ... the decline has been most prominent in May, which accounts ...
... Service scientists with the Institute of Pacific Islands Forestry ... to control the spread of strawberry guava, a South ... ecosystems since it was introduced in 1825 as a ... the Hawai Department of Land and Natural Resources, and ...
... An international team of scientists surveying the waters ... North America has discovered for the first time high ... the shoreline, raising concern for marine ecosystems from Canada ... State University research vessel, also discovered that this corrosive, ...
Cached Biology News:Understanding autumn rain decline in SE Australia 2Insect release proposed to control exotic strawberry guava 2Pacific coast turning more acidic 2Pacific coast turning more acidic 3
Request Info...
D-biotin *50 mM aqueous solution* Secondary Detection Biotin–Avidin Detection Reagents Other...
... BL21 Star strains ... designed for improved protein ... expression systems (Figure 1). ... polymerase synthesizes mRNA more ...
Green Standard is fluorescein....
Biology Products: